| (210) | Number of the EPO application | 17718256 |
| (220) | Filing date of the EPO application | 2017.04.04 |
| (80) | EPO patent specification publication (B) | EPB nr. 30/2024, 2024.07.24 |
| (110) | EPO patent number | 3439662 |
| (21) | Number of the application | e 2019 0186 |
| (71) | Name(s) of applicant(s), code of the country | Loxo Oncology Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | REYNOLDS Mark, US;
SMITH Steven A., US; |
| (73) | Name(s) of owner(s), code of the country | Loxo Oncology, Inc., US; |
| (54) | Title of the invention | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 31/519 (2006.01.01); A61P 35/00 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2019.03.31 |
| (30) | Priority | 201662318041 P, 2016.04.04, US; 201662323452 P, 2016.04.15, US; 201662329561 P, 2016.04.29, US |
| (86) | International application | PCT/US2017/025939, 2017.04.04 |
| (87) | International publication | WO 2017/176751, 2017.10.12 |